Array CGH analysis at 60kb resolution of CML samples at advanced stage of disease
Array CGH analysis at 60kb resolution of CML samples at advanced stage of disease
In spite of the universal presence of the BCR/ABL1 fusion gene, chronic myelogenous leukemia (CML) shows remarkable clinical and genetic diversity. The consequences of der(9)t(9;22) chromosome deletions, associated with poor survival, as well as the mechanism behind their formation remain unclear, as does our understanding of the molecular events driving the disease evolution. The presence of these deletions fuelled the expectations that cryptic genome-wide aberrations may be accountable for the disease progression. Following a comprehensive BAC aCGH analysis of 48 CML samples (Brazma et al., Genes, Chromosomes & Cancer, 2007 in press) we report high-resolution oligo-nucleotide array study of a further 30 CML accelerated/ blast phase samples. We were unable to confirm the high frequency of particular single BAC imbalances (CNVs), reported both by ourselves and others, possibly due to the manufacturer’s array selection strategy. Never-the-less some of the CNVs and a wealth of new imbalances were obtained at 60kb resolution. It was possible to build a precise map of the amplicon affecting the sequences flanking the 3' ABL1 breakpoint site, which include the LAMC3 and NUP214 genes. The presence of this amplicon was associated with therapy resistance. When assessed, at a resolution of 60 kb, the deletions of the regions flanking the ABL1/BCR breakpoint showed novel features:
1. the genome loss affects preferentially both flanking sites as seen in 5 of the 6 ‘deleted’ samples and
2. the 120kb deletion identified is the smallest recorded so far.
Most of the major cytogenetic features of the samples were confirmed and a number of cryptic genome imbalances were detected, from 120kb to 10Mb in size, involving regions rich in genes, some already implicated in the pathogenesis of CML. Finally, recurrent micro aberrations of several adjacent oligo-nucleotides affecting non-coding sequences were detected in as many as 2/3 of the samples.
p.860A
Grace, Colin
ec6394df-52cd-4fd0-82d5-d952bf31f535
Brazma, Diana
d847fe3c-2426-4253-af1e-3510edf20db0
Chanalaris, Anastasios
72d46901-69ac-4892-b713-4963b1b5d14f
Howard, Julie
8370cad4-80aa-4d49-8c33-1e1ca85e54c3
Virgili, Anna
457de937-2e5e-469c-ae98-cda7e8731b28
Valgañon, Mikel
4b6d620d-f38b-49a2-a54a-87d63dc7f485
Cross, Nick
f87650da-b908-4a34-b31b-d62c5f186fe4
Apperley, Jane F.
bb44333d-1437-4eb8-876a-37332e9ffcbc
Nacheva, Elisabeth
e7d54b5e-27bb-419d-a8bd-37b176a1be3a
16 November 2007
Grace, Colin
ec6394df-52cd-4fd0-82d5-d952bf31f535
Brazma, Diana
d847fe3c-2426-4253-af1e-3510edf20db0
Chanalaris, Anastasios
72d46901-69ac-4892-b713-4963b1b5d14f
Howard, Julie
8370cad4-80aa-4d49-8c33-1e1ca85e54c3
Virgili, Anna
457de937-2e5e-469c-ae98-cda7e8731b28
Valgañon, Mikel
4b6d620d-f38b-49a2-a54a-87d63dc7f485
Cross, Nick
f87650da-b908-4a34-b31b-d62c5f186fe4
Apperley, Jane F.
bb44333d-1437-4eb8-876a-37332e9ffcbc
Nacheva, Elisabeth
e7d54b5e-27bb-419d-a8bd-37b176a1be3a
Grace, Colin, Brazma, Diana, Chanalaris, Anastasios, Howard, Julie, Virgili, Anna, Valgañon, Mikel, Cross, Nick, Apperley, Jane F. and Nacheva, Elisabeth
(2007)
Array CGH analysis at 60kb resolution of CML samples at advanced stage of disease.
Blood, 110 (11), .
Abstract
In spite of the universal presence of the BCR/ABL1 fusion gene, chronic myelogenous leukemia (CML) shows remarkable clinical and genetic diversity. The consequences of der(9)t(9;22) chromosome deletions, associated with poor survival, as well as the mechanism behind their formation remain unclear, as does our understanding of the molecular events driving the disease evolution. The presence of these deletions fuelled the expectations that cryptic genome-wide aberrations may be accountable for the disease progression. Following a comprehensive BAC aCGH analysis of 48 CML samples (Brazma et al., Genes, Chromosomes & Cancer, 2007 in press) we report high-resolution oligo-nucleotide array study of a further 30 CML accelerated/ blast phase samples. We were unable to confirm the high frequency of particular single BAC imbalances (CNVs), reported both by ourselves and others, possibly due to the manufacturer’s array selection strategy. Never-the-less some of the CNVs and a wealth of new imbalances were obtained at 60kb resolution. It was possible to build a precise map of the amplicon affecting the sequences flanking the 3' ABL1 breakpoint site, which include the LAMC3 and NUP214 genes. The presence of this amplicon was associated with therapy resistance. When assessed, at a resolution of 60 kb, the deletions of the regions flanking the ABL1/BCR breakpoint showed novel features:
1. the genome loss affects preferentially both flanking sites as seen in 5 of the 6 ‘deleted’ samples and
2. the 120kb deletion identified is the smallest recorded so far.
Most of the major cytogenetic features of the samples were confirmed and a number of cryptic genome imbalances were detected, from 120kb to 10Mb in size, involving regions rich in genes, some already implicated in the pathogenesis of CML. Finally, recurrent micro aberrations of several adjacent oligo-nucleotides affecting non-coding sequences were detected in as many as 2/3 of the samples.
This record has no associated files available for download.
More information
Published date: 16 November 2007
Additional Information:
ASH Annual Meeting Abstracts 2007: abstract 2927
Identifiers
Local EPrints ID: 60596
URI: http://eprints.soton.ac.uk/id/eprint/60596
ISSN: 0006-4971
PURE UUID: 98b3c1e1-d250-4b1b-970a-3baf8acd270f
Catalogue record
Date deposited: 07 Nov 2008
Last modified: 23 Jul 2022 01:49
Export record
Contributors
Author:
Colin Grace
Author:
Diana Brazma
Author:
Anastasios Chanalaris
Author:
Julie Howard
Author:
Anna Virgili
Author:
Mikel Valgañon
Author:
Jane F. Apperley
Author:
Elisabeth Nacheva
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics